The FlexISH assay brings flexibility to cytogenetic HER2 testing.

Abstract

AIMS Fluorescence in-situ hybridization (FISH) is the method of choice for quantitative human epidermal growth factor receptor 2 (HER2) (also known as ERBB2) gene testing in invasive breast cancer. HER2 testing has great clinical impact, and is often claimed to expeditiously complete the entire diagnostic procedure for an individual patient. Against this… (More)
DOI: 10.1111/his.12974

Topics

4 Figures and Tables

Cite this paper

@article{Brockhoff2016TheFA, title={The FlexISH assay brings flexibility to cytogenetic HER2 testing.}, author={Gero Brockhoff and Maria Bock and Florian Zeman and Sven Hauke}, journal={Histopathology}, year={2016}, volume={69 4}, pages={635-46} }